A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Food Effect of SXC-2023 When Administered Orally to Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2018
At a glance
- Drugs SXC-2023 (Primary)
- Indications Psychiatric disorders
- Focus Adverse reactions
- Sponsors Promentis Pharmaceuticals
- 15 Mar 2018 Status changed from recruiting to completed.
- 16 Jan 2018 Planned number of patients changed from 40 to 48.
- 10 Oct 2017 New trial record